Adenosine Or Derivative Patents (Class 514/46)
-
Publication number: 20100152127Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described here.Type: ApplicationFiled: February 24, 2010Publication date: June 17, 2010Applicant: University of Virginia Patent FoundationInventors: Joel M. Linden, Jayson M. Rieger, Timothy L. Macdonald, Gail W. Sullivan, Lauren Jean Murphree, Robert Alan Figler
-
Publication number: 20100151042Abstract: The subject invention provides materials and methods for treating various health conditions, including the prevention and/or treatment of an influenza viral infection. In a preferred embodiment, a cysteamine compound and viral therapeutic are concurrently administered to a subject to treat an influenza virus infection. More preferably, a cysteamine compound is concurrently administered with a viral therapeutic to a subject to treat influenza A, influenza B, influenza C virus infections, including avian influenza virus subtypes (such as H5N1 avian influenza virus).Type: ApplicationFiled: May 27, 2008Publication date: June 17, 2010Inventors: Hao Yi Liang, Francis Chi, Qingfu Xu, Bill Piu Chan
-
Patent number: 7737127Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described here.Type: GrantFiled: March 26, 2007Date of Patent: June 15, 2010Assignee: University of Virginia Patent FoundationInventors: Joel M. Linden, Jayson M. Rieger, Timothy L. Macdonald, Gail W. Sullivan, Lauren Jean Murphree, Robert Alan Figler
-
Patent number: 7737126Abstract: A compound of formula (I) and salts and solvates thereof are disclosed. Compounds of formula (I) are agonists of the adenosine A2A receptor and are believed to be of potential use in the treatment of inflammatory diseases such as asthma and chronic obstructive pulmonary disease.Type: GrantFiled: May 23, 2005Date of Patent: June 15, 2010Assignee: Glaxo Group LimitedInventors: Philip Blatcher, Richard Peter Charles Cousins, Derek Norman Evans
-
Patent number: 7736636Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of Nicotine, nicotinic acid analogs thereof, their combination with or without other pro-angiogenesis factors, vasodilator, or other therapeutic modalities to promote angiogenesis in the subject. This is composition and combination thereof is applicable to improving wound healing, erectile dysfunction, improving collateral or blood supply in patients with myocardial infarction, stroke, peripheral artery diseases, and other vascular disorders as disclosed.Type: GrantFiled: February 11, 2004Date of Patent: June 15, 2010Inventors: Shaker Mousa, Sarah Mousa
-
Publication number: 20100143296Abstract: The present invention relates to new podophyllotoxin inhibitors of topoisomerase II, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: December 10, 2009Publication date: June 10, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventor: Thomas G. Gant
-
Publication number: 20100143295Abstract: The present invention relates to new quinazoline inhibitors of EGFR tyrosine kinase, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: December 4, 2009Publication date: June 10, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20100143289Abstract: Compositions including topical formulations comprising secreted products obtained from the culture medium of human umbilical cord stem cells and particular combinations of components therefrom are provided for treatment of various dermatological conditions, such as adverse consequences of aging, wrinkling, altered pigmentation, altered viscoelasticity, and altered thickness, among others. Methods for using the compositions and topical formulations for treating adverse or undesirable dermatological conditions are also provided, as well as preventing the appearance of undesirable dermatological conditions.Type: ApplicationFiled: December 19, 2007Publication date: June 10, 2010Inventors: Michael Cohen, Jacob Cohen
-
Patent number: 7732424Abstract: The present invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's core body temperature, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ophthalmic condition, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof.Type: GrantFiled: November 30, 2006Date of Patent: June 8, 2010Assignee: Inotek Pharmaceuticals CorporationInventors: Prakash Jagtap, Andrew L. Salzman
-
Publication number: 20100129353Abstract: This invention is directed towards treatments for multiple sclerosis comprising administering to a patient in need thereof a first agent, such as 2-chloro-2?-deoxyadenosine (2-CdA), that reduces the number of lymphocytes in combination with a second agent, such as an anti-alpha-4 integrin antibody, that blocks the adhesion of monocytes and leukocytes to endothelial cells. The use of 2-CdA combined with an anti-alpha-4 integrin antibody may be more effective than either treatment alone for MS. Furthermore, the combination treatment may allow for a lowering or altering the dose of one or more of the agents in order to limit any adverse effects associated with the individual agents, but maintaining the same therapeutic efficacy.Type: ApplicationFiled: December 20, 2005Publication date: May 27, 2010Applicant: Laboratoires Serono S.A.Inventor: Giampiero De Luca
-
Publication number: 20100129321Abstract: The present invention relates to pharmaceutical compositions for treating virus infections and/or diseases caused thereby comprising 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide optionally combined with at least one additional therapeutic agent.Type: ApplicationFiled: December 6, 2006Publication date: May 27, 2010Applicant: BAYER HEALTHCARE LLCInventors: Olaf Weber, Bernd Riedl
-
Publication number: 20100119554Abstract: The present invention relates to a method of reducing injury to cells, a tissue or organ to be explanted from a body and upon implantation into a body by administering a composition to the cell, tissue or organ, including: (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and (ii) an antiarrhythmic agent. The invention also provides a composition for reducing injury to vasculature ex vivo including: (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and (ii) an antiarrhythmic agent.Type: ApplicationFiled: March 3, 2008Publication date: May 13, 2010Applicant: Hibernation Therapeutics LimitedInventor: Geoffrey Phillip Dobson
-
Publication number: 20100119479Abstract: Disclosed herein are compounds represented by a formula: Therapeutic methods, compositions, medicaments, and dosage forms related thereto are also disclosed.Type: ApplicationFiled: October 14, 2009Publication date: May 13, 2010Applicant: INTERMUNE, INC.Inventors: BRAD BUCKMAN, VLADIMIR SEREBRYANY, SCOTT SEIWERT, LEONID BEIGELMAN, ANTITSA STOYCHEVA
-
Patent number: 7713946Abstract: Disclosed are novel compounds a compound of Formula I that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular dyslipidemia, diabetes, decreased insulin sensitivity, Polycystic Ovarian Syndrome, Stein-Leventhal syndrome, and obesity.Type: GrantFiled: December 18, 2006Date of Patent: May 11, 2010Assignee: CV Therapeutics, Inc.Inventors: Arvinder Dhalla, Elfatih Elzein, Prabha Ibrahim, Venkata Palle, Vaibhav Varkhedkar, Jeff Zablocki
-
Patent number: 7713947Abstract: The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be orally administered and wherein re-treatments are possible.Type: GrantFiled: December 20, 2005Date of Patent: May 11, 2010Assignee: Merck Serono S.A.Inventors: Giampiero De Luca, Arnaud Ythier, Alain Munafo, Maria Lopez-Bresnahan
-
Publication number: 20100112079Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.Type: ApplicationFiled: November 25, 2009Publication date: May 6, 2010Applicant: Ordway Research Institute, Inc.Inventors: Shaker A. Mousa, Faith B. Davis, Paul J. Davis
-
Publication number: 20100113379Abstract: The present invention relates to the induction of autophagy via mTOR independent pathways which modulated intracytosolic cAMP levels. In some embodiments, autophagy may be induced in a cell by reducing intracytosolic cAMP levels, for example using a cAMP antagonist, such as clonidine. This may be useful, for example in the treatment of neurodegenerative disorders or pathogen infections.Type: ApplicationFiled: February 14, 2008Publication date: May 6, 2010Inventors: David Rubinsztein, Sovan Sarkar, Andrea Williams
-
Patent number: 7709449Abstract: The invention provides compounds capable of treating against hepatitis infections, particularly hepatitis B viral infections. Compounds of the invention are nucleic acid-based and preferably comprise 2, 3, 4, 5 or 6 nucleoside units.Type: GrantFiled: July 10, 2007Date of Patent: May 4, 2010Assignee: Migenix, Inc.Inventors: Radhakrishnan P. Iyer, Yi Jin, Arlene Roland, Wenqiang Zhou
-
Publication number: 20100106244Abstract: A stent is coated with 3-deazaadenosine or an analog of 3-deazaadenosine for the prevention and/or treatment of vascular disease or graft rejection.Type: ApplicationFiled: November 4, 2009Publication date: April 29, 2010Inventor: Werner Haberbosch
-
Publication number: 20100105758Abstract: Uses for a selective adenosine A3 receptor antagonist, or RNAi directed against said receptor, to treat myocardial infarction and heart conditions including heart failure, are provided. Optionally, an adenosine A2a receptor agonist may also be used with the adenosine A3 receptor antagonist. Methods of treating heart failure are also provided.Type: ApplicationFiled: November 8, 2007Publication date: April 29, 2010Applicant: Centre de Recherche Public de la SanteInventors: Daniel R. Wagner, Yvan Devaux
-
Publication number: 20100098753Abstract: The present invention relates to a novel preventive and/or therapeutic drug for myocardial infarction. The present invention provides a preventive and/or therapeutic drug for myocardial infarction or myocardial ischemia-reperfusion injury, the drug containing a lipid membrane structure retaining adenosine.Type: ApplicationFiled: September 18, 2009Publication date: April 22, 2010Applicants: Osaka University, JAPAN AS REP. BY THE PRES. OF NAT'L. CARDIO. CENTR, DAIICHI SANKYO COMPANY, LIMITEDInventors: Tetsuo MINAMINO, Masafumi Kitakaze, Masatsugu Hori, Hiroyuki Takahama, Hiroshi Kikuchi, Kouichi Hashimoto, Hideo Kobayashi, Ayako IIJIMA, Daigo Asano
-
Publication number: 20100099642Abstract: The invention relates to the use of TGF-beta stimulating agents, and in particular members of the triphenylethylene class of pharmaceutical agents, for the prevention, prophylaxis, treatment or amelioration of symptoms of cardiovascular disease, autoimmune diseases or neurodegeneration. In particular, improved compositions consisting of triphenylethylene agents combined with one or more additional active pharmaceutical agents in order to mitigate against side-effects of the triphenylethylene are described and claimed.Type: ApplicationFiled: February 7, 2008Publication date: April 22, 2010Applicant: TCP Innovations LimitedInventor: David J. Grainger
-
Patent number: 7696181Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, myocardial infarction and hyperlipidemia. The structure of the compounds is given by Formula (I): wherein R1, R2, R3, R4, R5, X, Y, Z, and T are as described herein.Type: GrantFiled: August 24, 2006Date of Patent: April 13, 2010Assignee: CV Therapeutics, Inc.Inventors: Prabha Ibrahim, Elfatih Elzein, Kevin Shenk, Robert Jiang, Jeff Zablocki, Xiaofen Li, Christopher Morrison, Thao Perry, Dengming Xiao
-
Publication number: 20100086483Abstract: This invention relates to methods for multidetector computed tomography myocardial perfusion imaging comprising administering doses of a rate-control agent and one or more adenosine A2A receptor agonists to a mammal.Type: ApplicationFiled: September 29, 2009Publication date: April 8, 2010Inventors: Luiz Belardinelli, Brent Blackburn
-
Patent number: 7691825Abstract: The present invention provides compounds of the formula wherein R1, R2, R3 and n have meaning as described in the specification, methods for their preparation, and pharmaceutical compositions containing them. The compounds of formula (I) are adenosine A2B receptor agonists and, thus, may be employed for the treatment of diseases in mammals that are mediated by the A2B receptor including, but not limited to, septic shock, cystic fibrosis, impotence, diarrhea, and cardiac diseases. Cardiac diseases include hyperplasia consequent to hypertension, arteriosclerosis, and heart attack. The present invention also provides methods for the induction of pharmacological stress to facilitate coronary imaging of areas of ischemia by employing compounds of formula (I). The compounds of formula (I) may be labeled, e.g., with radioactive isotopes, and therefore are useful in kinetic binding experiments.Type: GrantFiled: June 4, 2007Date of Patent: April 6, 2010Assignee: King Pharmaceuticals Research and Development, Inc.Inventors: Pier Giovanni Baraldi, Pier Andrea Borea, Allan R. Moorman, Delia Preti
-
Patent number: 7683037Abstract: The present invention relates to methods for myocardial imaging by administering at least one 2-adenosine N-pyrazole, 2-adenosine C-pyrazole or a combination thereof A2A adenosine receptor agonist to a human undergoing myocardial imaging. The invention also relates to methods of producing coronary vasodilation without significant peripheral vasodilation by administering at least one 2-adenosine N-pyrazole, 2-adenosine C-pyrazole or a combination thereof adenosine A2A adenosine receptor agonist to a human.Type: GrantFiled: July 29, 2003Date of Patent: March 23, 2010Assignee: Gilead Palo Alto, Inc.Inventor: Luiz Belardinelli
-
Publication number: 20100068301Abstract: Disclosed herein are compositions and compounds that combine an inhibitor of 5-lipoxygenase activating protein (FLAP) and a modulator of NO levels in a mammal. The NO modulator can be an agent that induces the production of NO in a mammal, or can be an agent that itself produces NO in the mammal. Further disclosed herein are strategies for synthesizing such compounds, and methods for testing whether the combination compounds and compositions provide a desired benefit. Also disclosed herein are pharmaceutical compositions and formulations that combine a FLAP inhibitor and an NO modulator. Further described herein are methods for using such compositions and compounds for the treatment of diseases, conditions, and disorders in a mammal, including a human. Such treatment methods include the separate administration of a FLAP inhibitor and a NO modulator to the mammal, and the simultaneous administration of a FLAP inhibitor and a NO modulator to the mammal.Type: ApplicationFiled: November 30, 2007Publication date: March 18, 2010Inventors: John H. Hutchinson, Mustapha Haddach, Mark Moran, Jillian Evans, Nicholas Simon Stock, Jeffrey Roger Roppe
-
Publication number: 20100062993Abstract: It is the embodiment of this invention that Methylthioadenosine and its pharmaceutically acceptable salts as dietary supplements are more efficient, more economical and better tolerated than conventional existing dietary supplements such as S-Adenosylmethionine in the promotion of normal cell growth. It is a further embodiment of this invention that Methylthioadenosine and its pharmaceutically acceptable salts as dietary supplements are more efficient, more economical and better tolerated than conventional existing dietary supplements such as S-Adenosylmethionine in the destruction of aberrant cells that can cause various cancer.Type: ApplicationFiled: September 11, 2008Publication date: March 11, 2010Inventor: Yochanan R. Bulka
-
Publication number: 20100062994Abstract: The present application discloses locked nucleoside compounds of the Formula I which act as antagonists of adenosine receptors, in particular the adenosine A3 receptor, and the use of such adenosine A3 receptor compounds in medicine, e.g.Type: ApplicationFiled: July 6, 2007Publication date: March 11, 2010Applicant: SANTARIS PHARMA A/SInventors: Jacob Ravn, Christoph Rosenbohm, Katrine Qvortrup, Troels Koch
-
Publication number: 20100056465Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.Type: ApplicationFiled: September 4, 2009Publication date: March 4, 2010Applicant: Ardea BiosciencesInventors: Esmir Gunic, Jean-Luc Girardet, Jean-Michel Vernier, Martina E. Tedder, David A. Paisner
-
Patent number: 7671038Abstract: The administration of adenine nucleotides or adenosine and inorganic phosphate to a human host results in the generation of elevated liver, other organs and red blood cell adenosine 5?-triphosphate (ATP) pools as well as increased levels of ATP and adenosine in the extracellular blood plasma compartment of the blood. The present invention deals with the utilization of the elevated intracellular ATP levels and the elevated extracellular levels of ATP and adenosine for the treatment of a broad spectrum of clinical targets in HIV disease/AIDS and the achievement of decisive therapeutic gains.Type: GrantFiled: October 8, 1993Date of Patent: March 2, 2010Inventor: Eliezer Rapaport
-
Publication number: 20100048500Abstract: The present invention relates to novel compounds according to the general formulas I, II, III, IV or V: wherein B is nucleoside base according to the structure: and the remaining variables as defined in the specification, and pharmaceutical compositions comprising the compounds. The compounds are useful interalia as anti-viral agents in viral therapy.Type: ApplicationFiled: August 17, 2009Publication date: February 25, 2010Inventors: Yung-chi Cheng, Hiromichi Tanaka, Masanori Baba
-
Patent number: 7662361Abstract: The invention provides methods and compositions for modulating the activity of therapeutic agents for the treatment of a cancer by administering one or more agents that (either alone or in combination) induces telomere damage and inhibits telomerase activity in the cancer cell. The method initially uses, e.g., a telomere damage-inducing agent such as paclitaxel, and a telomerase inhibitory agent such as AZT. The invention also provides methods for identifying other agents with telomere damage-inducing activity and/or telomerase inhibitory activity (as well as and compositions having such activity), for use in the treatment of cancer.Type: GrantFiled: February 2, 2006Date of Patent: February 16, 2010Inventors: Jessie L.-S. Au, M. Guillaume Wientjes
-
Patent number: 7655636Abstract: The present invention relates to methods for producing coronary vasodilation with little peripheral vasodilation by administering doses of a pharmaceutical composition including regadenoson, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, — an adenosine A2A receptor agonist — to a human in an amount sufficient to increase the average coronary peak flow velocity by at least about 16.5 cm/sec.Type: GrantFiled: October 19, 2005Date of Patent: February 2, 2010Assignee: Gilead Palo Alto, Inc.Inventors: Toufigh Gordi, Ann Walls Olmsted, Hsiao Dee Lieu, Luiz Belardinelli
-
Patent number: 7655637Abstract: 2-adenosine N-pyrazole compounds having the following formula: wherein R1?CH2OH; R2 is hydrogen; R3 is selected from the group consisting of CO2R20; —CONR7R8 ,and aryl wherein the aryl substituent is optionally substituted with one substituent selected from the group consisting of halo, C 1-3alkyl and OR20;R4 is hydrogen; R7 is selected from hydrogen, and C1-3alkyl; R8 is hydrogen; and R20 is selected from hydrogen and methyl as well as methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart are disclosed.Type: GrantFiled: October 27, 2006Date of Patent: February 2, 2010Assignee: Gilead Palo Alto, Inc.Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata Palle, Luiz Belardinelli
-
Patent number: 7655638Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.Type: GrantFiled: November 15, 2006Date of Patent: February 2, 2010Assignee: Gilead Palo Alto, Inc.Inventors: Elfatih Elzein, Prabha Ibrahim, Venkata Palle, Vaibhav Varkhedkar, Jeff Zablocki
-
Publication number: 20100004192Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.Type: ApplicationFiled: September 14, 2009Publication date: January 7, 2010Inventors: Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Nobuo Shimma, Takuo Tsukuda
-
Publication number: 20100003193Abstract: The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging.Type: ApplicationFiled: July 2, 2009Publication date: January 7, 2010Applicant: University of Virginia Patent FoundationInventors: Robert Hendel, William B. Stilley, Shannon P. Williams
-
Publication number: 20100003213Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.Type: ApplicationFiled: September 16, 2009Publication date: January 7, 2010Inventors: Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
-
Publication number: 20100004191Abstract: Compositions of S-adenosyl-L-methionine with indole-3-propionic acid and methods to treat conditions associated with DNA hypomethylation are disclosed.Type: ApplicationFiled: July 1, 2008Publication date: January 7, 2010Inventor: Rolland F Hebert
-
Publication number: 20090325896Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, myocardial infarction and hyperlipidemia.Type: ApplicationFiled: July 23, 2009Publication date: December 31, 2009Inventors: Prabha Ibrahim, Elfatih Elzein, Kevin Shenk, Robert Jiang, Jeff Zablocki, Xiaofein Li, Christopher Morrison, Thao Perry, Dengming Xiao
-
Publication number: 20090325878Abstract: The present invention relates to a method for reducing electrical disturbance of a cell's resting membrane potential comprising administering an effective amount of a composition comprising an effective amount of a local anaesthetic and of one or more of a potassium channel opener, an adenosine receptor agonist, an anti-adrenergic, a calcium antagonist, an opioid, an NO donor and a sodium hydrogen exchange inhibitor.Type: ApplicationFiled: May 26, 2009Publication date: December 31, 2009Applicant: Hibernation Therapeutics LimitedInventor: Geoffrey Phillip Dobson
-
Publication number: 20090324748Abstract: The invention provides a method of reducing injury to cells, tissues or organs of a body following trauma by administering a composition to the body following trauma, including: (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and (ii) a local anaesthetic. Also provided is a composition for reducing injury to cells, tissues or organs of a body following trauma including: (i) and (ii). The composition may be hypertonic.Type: ApplicationFiled: July 25, 2007Publication date: December 31, 2009Applicant: Hibernation Therapeutics LimitedInventor: Geoffrey Philip Dobson
-
Publication number: 20090317463Abstract: The present invention relates to solid dietary and/or nutraceutic pharmaceutical compositions for oral use based on SAMe, or salts thereof, in combination with inositol and/or derivatives thereof and to a process for their preparation. The present invention relates to a method of stabilising a solid composition for oral use based on SAMe or salts thereof, making use of inositol and/or derivatives thereof with the addition of magnesium oxide. The present invention also relates to the use of SAMe, or salts thereof, in combination with inositol and/or derivatives thereof with the possible further addition of melatonine, St. John's Wort and/or lemon balm for the treatment of depressive states and/or panic syndromes.Type: ApplicationFiled: November 15, 2006Publication date: December 24, 2009Inventors: Alessandro Seneci, Daniele Giovannone, Cesare Zio
-
Publication number: 20090317331Abstract: The present invention provides a method for identifying and using partial adenosine A2A receptor agonists that are useful as adjuncts in myocardiological perfusion imaging.Type: ApplicationFiled: May 4, 2009Publication date: December 24, 2009Inventors: Luiz Belardinelli, Brent K. Blackburn, Zhenhai Gao
-
Patent number: 7635689Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.Type: GrantFiled: December 6, 2004Date of Patent: December 22, 2009Assignees: Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique, L'Universite Montpellier IIInventors: Paola LaColla, Richard Storer, Gilles Gosselin, Jean-Pierre Sommadossi
-
Patent number: 7635690Abstract: The present invention discloses a method for treating HIV that includes administering ?-D-D4FC or its pharmaceutically acceptable salt or prodrug to a human in need of therapy in combination or alternation with a drug that induces a mutation in HIV-1 at a location other than the 70(K to N), 90 or the 172 codons of the reverse transcriptase region. Also disclosed is a method for using ?-D-D4FC as “salvage therapy” to patients which exhibit drug resistance to other anti-HIV agents. ?-D-D4FC can be used generally as salvage therapy for any patient which exhibits resistance to a drug that induces a mutation at other than the 70(K to N), 90 or the 172 codons.Type: GrantFiled: October 3, 2006Date of Patent: December 22, 2009Assignee: Emory UniversityInventors: Raymond F. Schinazi, Jennifer L. Hammond, John W. Mellors, Dennis C. Liotta
-
Patent number: 7632825Abstract: Methods of providing pain relief by administering a water-soluble derivative of spicamycin. Methods of using pain mediation agents are also provided.Type: GrantFiled: April 30, 2008Date of Patent: December 15, 2009Assignee: Bayer Pharmaceuticals CorporationInventor: David Borsook
-
Publication number: 20090297567Abstract: A method is provided for site specific delivering therapeutic or diagnostic agents to a region in a fluid-filled cavity, vessel or tissue using an agent-loaded microbubble population. The population has controlled fragility characterized by a uniform wall thickness to diameter ratio which defines the discrete threshold intensity value of ultrasonic power where microbubble rupture occurs in the population. The location of the microbubble population may be monitored by ultrasound to determine its presence at the region prior to application of the ultrasonic power to rupture to microbubbles.Type: ApplicationFiled: August 12, 2009Publication date: December 3, 2009Inventors: Stanley R. Conston, Ronald Yamamoto, Thomas B. Ottoboni, E. Glenn Tickner
-
Publication number: 20090298789Abstract: The present invention relates to a method for arresting, protecting and/or preserving an organ which includes administering effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) local anaesthetic to a subject in need thereof. The present invention also relates to a method for arresting, protecting and/or preserving an organ which comprises adding a composition which includes effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic to the organ. The present invention further provides a pharmaceutical or veterinary composition which includes effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic.Type: ApplicationFiled: August 13, 2009Publication date: December 3, 2009Applicant: Hibernation Therapeutics LimitedInventor: Geoffrey Phillip Dobson